SPOP and cancer: Our findings showed that SPOP-mutant cancer cells were at a higher risk of NE rupture and may be more susceptible to farnesyltransferase inhibition, providing a potential therapeutic avenue for targeting cancers with a high risk of NE rupture, such as those with SPOP mutations.